Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe"

Immunobiology. 2012 Jun;217(6):590-2. doi: 10.1016/j.imbio.2011.11.001. Epub 2011 Nov 17.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • CTLA-4 Antigen / antagonists & inhibitors*
  • Humans
  • Immunization, Passive / methods*
  • Ipilimumab
  • Melanoma / therapy*
  • Skin Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal
  • CTLA-4 Antigen
  • Ipilimumab